Introduction and vote

Date 01 October 2012
Event ESMO Congress 2012
Session EGFR inhibitors are the best choice for the first line treatment of EGFR mutated lung adenocarcinoma patients
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Fortunato Ciardiello
Authors F. Ciardiello
  • Dip. Medico Chirurgico Di Internistica, Seconda Università Studi di Napoli Policlinico Federico II, 80131 - Napoli/IT